- $1.92bn
- $1.57bn
- $125.58m
Brief: Xencor's IL2-FC Cytokine, XmAb564, Is Well-Tolerated, Selectively Expands Regulatory T Cells In Phase 1A Clinical Study
Brief: Xencor Reports Q3 Loss Per Share Of $0.55
Xencor Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Xencor Appoints Nancy Valente, M.D., To Board Of Directors
Brief: Xencor Q2 Loss Per Share $0.57
Brief: Xencor Inc - Caris Life Sciences And Xencor Enter Target Discovery Collaboration And License Agreement For Novel XmAb Bispecific Antibodies
Brief: Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of Xmab®104, Pd-1 X Icos Bispecific Antibody, In Advanced Solid Tumors
Brief: Xencor Reports First Quarter 2022 Financial Results
Xencor Inc expected to post a loss of 61 cents a share - Earnings Preview
Xencor Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Xencor Reports Q4 And Full Year 2021 Financial Results
Xencor Inc reports results for the quarter ended in December - Earnings Summary
Xencor Inc expected to post a loss of 10 cents a share - Earnings Preview
Xencor Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Xencor Presents Data From Phase 1 Study Of Plamotamab In B-Cell Non-Hodgkin Lymphomas At ASH Annual Meeting
Pfizer sues departing employee it says stole COVID-19 vaccine secrets
Brief: Xencor Presents Data From Multiple Preclinical XmAb Bispecific Antibody Programs, IL-12 Cytokine, XmAb662
Brief: Xencor Presents Updated Data From Phase 1 Study Of Vudalimab, PD-1 X CTLA-4 Bispecific Antibody
Xencor Inc reports results for the quarter ended in September - Earnings Summary